264 related articles for article (PubMed ID: 19721237)
1. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines.
Fujimoto H; Higuchi M; Watanabe H; Koh Y; Ghosh AK; Mitsuya H; Tanoue N; Hamada A; Saito H
Biol Pharm Bull; 2009 Sep; 32(9):1588-93. PubMed ID: 19721237
[TBL] [Abstract][Full Text] [Related]
2. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents.
Hashiguchi Y; Hamada A; Shinohara T; Tsuchiya K; Jono H; Saito H
Biochem Biophys Res Commun; 2013 Sep; 439(2):221-7. PubMed ID: 23981805
[TBL] [Abstract][Full Text] [Related]
3. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
4. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
Kuteykin-Teplyakov K; Luna-Tortós C; Ambroziak K; Löscher W
Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
[TBL] [Abstract][Full Text] [Related]
5. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
[TBL] [Abstract][Full Text] [Related]
6. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein.
Iwai M; Minematsu T; Li Q; Iwatsubo T; Usui T
Drug Metab Dispos; 2011 Dec; 39(12):2314-20. PubMed ID: 21918035
[TBL] [Abstract][Full Text] [Related]
7. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
8. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
[TBL] [Abstract][Full Text] [Related]
10. Interaction of docetaxel ("Taxotere") with human P-glycoprotein.
Shirakawa K; Takara K; Tanigawara Y; Aoyama N; Kasuga M; Komada F; Sakaeda T; Okumura K
Jpn J Cancer Res; 1999 Dec; 90(12):1380-6. PubMed ID: 10665657
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of multidrug resistance by adamantylgb3, a globotriaosylceramide analog.
De Rosa MF; Ackerley C; Wang B; Ito S; Clarke DM; Lingwood C
J Biol Chem; 2008 Feb; 283(8):4501-11. PubMed ID: 18003606
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
13. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
Honda Y; Ushigome F; Koyabu N; Morimoto S; Shoyama Y; Uchiumi T; Kuwano M; Ohtani H; Sawada Y
Br J Pharmacol; 2004 Dec; 143(7):856-64. PubMed ID: 15504753
[TBL] [Abstract][Full Text] [Related]
14. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein.
Wandel C; Kim R; Wood M; Wood A
Anesthesiology; 2002 Apr; 96(4):913-20. PubMed ID: 11964599
[TBL] [Abstract][Full Text] [Related]
15. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
17. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
18. Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.
Tanaka K; Hirai M; Tanigawara Y; Ueda K; Takano M; Hori R; Inui K
Biochem Pharmacol; 1997 Mar; 53(5):741-6. PubMed ID: 9113094
[TBL] [Abstract][Full Text] [Related]
19. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers.
Soldner A; Benet LZ; Mutschler E; Christians U
Br J Pharmacol; 2000 Mar; 129(6):1235-43. PubMed ID: 10725273
[TBL] [Abstract][Full Text] [Related]
20. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells.
Haslam IS; Jones K; Coleman T; Simmons NL
Br J Pharmacol; 2008 May; 154(1):246-55. PubMed ID: 18332862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
